ORIC Pharmaceuticals (ORIC) PT Raised to $18 at Stifel

Sun, 25 Oct 2026 18:35:56 -0400

Stifel analyst Laura Prendergast raised the price target on ORIC Pharmaceuticals (NASDAQ: ORIC) to $18.00 (from $14.00) while maintaining a Buy rating.

The analyst comments "At ESMO there were numerous de-risking presentations for ORIC that motivated us to raise our TP to $18 (previously $14, maintaining Buy rating) ahead of the MEVPRO-1 binary: (1) enozertinib poster, (2) PFE's mevrometostat mCRPC monotherapy poster, and (3) preclinical rinzimetostat poster. While we see near term upside potential for ORIC beyond what is captured in our TP, we remain conservative given: (1) the trickiness of topline binary readthroughs from pharma (limited info in PR expected),

ORIC Pharmaceuticals (ORIC) PT Raised to $18 at Stifel

Sun, 25 Oct 2026 18:35:56 -0400

Stifel analyst Laura Prendergast raised the price target on ORIC Pharmaceuticals (NASDAQ: ORIC) to $18.00 (from $14.00) while maintaining a Buy rating.

Form 8-K Oric Pharmaceuticals, For: Oct 23

Fri, 23 Oct 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20261023/27225190.html

ORIC Pharmaceuticals shares rinzimetostat prostate cancer data at ESMO

Fri, 23 Oct 2026 06:03:26 -0400

ORIC Pharmaceuticals (NASDAQ: ORIC) presented preclinical and translational data at the ESMO Congress 2026 on Oct. 23, showing that its drug candidate rinzimetostat may enhance sensitivity to androgen receptor (AR) inhibition in prostate cancer.

The data, shared via an ePoster presentation, showed that prostate cancer cells that developed resistance to the EZH2 inhibitor mevrometostat acquired an EZH2 mutation against which rinzimetostat maintained its potency. No rinzimetostat-resistant cells emerged in the preclinical models tested.

Preclinical studies also showed no hematologic tumorigenesis with rinzimetostat in rat toxicology studies, contrasting with results observed with EZH2 inhibitor tazemetostat in similar models. The company said these findings

ORIC Pharmaceuticals reports enozertinib Phase 1b data in lung cancer

Fri, 23 Oct 2026 03:15:16 -0400

ORIC Pharmaceuticals (Nasdaq: ORIC) presented Phase 1b clinical data for enozertinib in first-line non-small cell lung cancer patients with EGFR atypical mutations at the ESMO Congress 2026, and announced plans to advance the drug into a global Phase 3 trial.

The data, based on a September 4, 2026 cutoff, covered 26 patients treated with 80 mg once-daily oral enozertinib. Of those patients, 65% had brain metastases at baseline and 46% had previously untreated brain metastases.

The trial reported an 84% confirmed systemic objective response rate by investigator assessment and 80% by blinded independent central review. The 6-month landmark progression-free survival rate was

ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phas

Fri, 23 Oct 2026 03:15:00 -0400

In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and 70% confirmed intracranial ORR, with multiple intracranial complete responses

88% 6-month landmark PFS compares favorably to current standards of care and to investigational therapies; follow-up ongoing with majority of patients continuing on treatment

Competitive safety profile with no significant off-target toxicity and no treatment-related discontinuations

Redwood-1 global Phase 3 registrational trial initiation in 1L EGFR atypical NSCLC expected in 1H 2027

ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phas

Fri, 23 Oct 2026 03:15:00 -0400

88% 6-month landmark PFS compares favorably to current standards of care and to investigational therapies; follow-up ongoing with majority of patients continuing on treatment

Competitive safety profile with no significant off-target toxicity and no treatment-related discontinuations

Redwood-1 global Phase 3 registrational trial initiation in 1L EGFR atypical NSCLC expected in 1H 2027

ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress

Fri, 23 Oct 2026 03:15:00 -0400

Preclinical data highlight potential advantages of targeting PRC2 via EED over EZH2, including the emergence of resistance mutations to EZH2 inhibitors like mevrometostat and against which the EED inhibitor rinzimetostat maintained effectiveness

Preclinical results, supported by translational data in mCRPC patient samples, show rinzimetostat reinforces a luminal, AR-dependent state, restricts lineage plasticity and enhances sensitivity to AR inhibition

Findings reinforce rinzimetostat’s differentiated profile and support development across the prostate cancer disease spectrum, including in the ongoing Himalayas-1 Phase 3 trial

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 23, 2026

ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress

Fri, 23 Oct 2026 03:15:00 -0400

Findings reinforce rinzimetostat’s differentiated profile and support development across the prostate cancer disease spectrum, including in the ongoing Himalayas-1 Phase 3 trial

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 23, 2026

Form 4 Oric Pharmaceuticals, For: Oct 20 Filed by: Piscitelli Dominic

Wed, 21 Oct 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20261021/27217310.html

ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026

Mon, 19 Oct 2026 08:00:00 -0400

Conference call and webcast to take place on Friday, October 23, 2026, at 8:00 a.m. ET

Event to feature Dr. Joshua Sabari to discuss enozertinib clinical data and the potential of enozertinib to treat first-line NSCLC patients with EGFR atypical mutations

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced a conference call and webcast to review clinical data from the

ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026

Mon, 19 Oct 2026 08:00:00 -0400

Conference call and webcast to take place on Friday, October 23, 2026, at 8:00 a.m. ET

Event to feature Dr. Joshua Sabari to discuss enozertinib clinical data and the potential of enozertinib to treat first-line NSCLC patients with EGFR atypical mutations

ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026

Mon, 19 Oct 2026 08:00:00 -0400

Conference call and webcast to take place on Friday, October 23, 2026, at 8:00 a.m. ET

Event to feature Dr. Joshua Sabari to discuss enozertinib clinical data and the potential of enozertinib to treat first-line NSCLC patients with EGFR atypical mutations

ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026

Mon, 19 Oct 2026 08:00:00 -0400

Conference call and webcast to take place on Friday, October 23, 2026, at 8:00 a.m. ET

Event to feature Dr. Joshua Sabari to discuss enozertinib clinical data and the potential of enozertinib to treat first-line NSCLC patients with EGFR atypical mutations

ORIC Pharmaceuticals (ORIC) PT Raised to $26 at JPMorgan

Wed, 14 Oct 2026 08:48:04 -0400

JPMorgan analyst Anupam Rama raised the price target on ORIC Pharmaceuticals (NASDAQ: ORIC) to $26.00 (from $23.00) while maintaining a Overweight rating.

ORIC Pharmaceuticals partners with Cancer Research UK on cancer drug

Mon, 05 Oct 2026 16:03:13 -0400

ORIC Pharmaceuticals (Nasdaq: ORIC) has signed an agreement with Cancer Research UK to advance ORIC-259, a small molecule drug candidate targeting CIP2A, into clinical development, according to a press release from the company.

Under the agreement, Cancer Research UK's Centre for Drug Development will fully fund, sponsor, design, and execute CTA-enabling studies and Phase 1/2 clinical development of ORIC-259 for cancer patients. ORIC retains an option to reacquire rights to ORIC-259 following Phase 1/2 data, with Cancer Research UK eligible to receive downstream milestone payments and royalties.

ORIC-259 is described by the company as a potent, selective, orally bioavailable small molecule degrader

ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development

Mon, 05 Oct 2026 16:01:00 -0400

ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target

Cancer Research UK to fully fund, sponsor, design, and execute CTA-enabling studies and Phase 1/2 clinical development

ORIC retains exclusive option to reacquire rights to ORIC-259 following Phase 1/2 data

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced an agreement with Cancer Research UK, one of the

ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development

Mon, 05 Oct 2026 16:01:00 -0400

ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target

Cancer Research UK to fully fund, sponsor, design, and execute CTA-enabling studies and Phase 1/2 clinical development

ORIC retains exclusive option to reacquire rights to ORIC-259 following Phase 1/2 data

Leerink Starts ORIC Pharmaceuticals (ORIC) at Outperform

Mon, 05 Oct 2026 06:09:43 -0400

Leerink analyst Asthika Goonewardene initiates coverage on ORIC Pharmaceuticals (NASDAQ: ORIC) with a Outperform rating and a price target of $26.00.

For an analyst ratings summary and ratings history on ORIC Pharmaceuticals click here. For more ratings news on ORIC Pharmaceuticals click here.

Shares of ORIC Pharmaceuticals closed at $12.21 yesterday.

Form 4 Oric Pharmaceuticals, For: Oct 01 Filed by: Heyman Richard A.

Fri, 02 Oct 2026 17:51:00 -0400

si-local-file:///var/storage/secattach/20261002/27143774.html

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:30:00 -0400

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 1, 2026 (the “Grant Date”), ORIC granted a total of 161,550 non-qualified stock options and 26,850 restricted stock units to six new non-executive employees who began their employment with ORIC in September 2026.

These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient’s continued employment or service through each

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:30:00 -0400

These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient’s continued employment or service through each

Form 144 Oric Pharmaceuticals, Filed by: Heyman Richard A.

Thu, 01 Oct 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20261001/27136323.html

Form 144 Oric Pharmaceuticals, Filed by: Heyman Richard A.

Thu, 01 Oct 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20261001/27136310.html

Form 4 Oric Pharmaceuticals, For: Sep 28 Filed by: Piscitelli Dominic

Tue, 29 Sep 2026 19:16:00 -0400

si-local-file:///var/storage/secattach/20260929/27123755.html

StreetInsider.com News Articles

ORIC Pharmaceuticals (ORIC) PT Raised to $18 at Stifel

ORIC Pharmaceuticals (ORIC) PT Raised to $18 at Stifel

Form 8-K Oric Pharmaceuticals, For: Oct 23

ORIC Pharmaceuticals shares rinzimetostat prostate cancer data at ESMO

ORIC Pharmaceuticals reports enozertinib Phase 1b data in lung cancer

ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phas

ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phas

ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress

ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress

Form 4 Oric Pharmaceuticals, For: Oct 20 Filed by: Piscitelli Dominic

ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026

ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026

ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026

ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026

ORIC Pharmaceuticals (ORIC) PT Raised to $26 at JPMorgan

ORIC Pharmaceuticals partners with Cancer Research UK on cancer drug

ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development

ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development

Leerink Starts ORIC Pharmaceuticals (ORIC) at Outperform

Form 4 Oric Pharmaceuticals, For: Oct 01 Filed by: Heyman Richard A.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Form 144 Oric Pharmaceuticals, Filed by: Heyman Richard A.

Form 144 Oric Pharmaceuticals, Filed by: Heyman Richard A.

Form 4 Oric Pharmaceuticals, For: Sep 28 Filed by: Piscitelli Dominic